Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets
- PMID: 38702756
- PMCID: PMC11067317
- DOI: 10.1186/s12967-024-05169-9
Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets
Abstract
The onerous health and economic burden associated with head and neck squamous cell carcinoma (HNSCC) is a global predicament. Despite the advent of novel surgical techniques and therapeutic protocols, there is an incessant need for efficacious diagnostic and therapeutic targets to monitor the invasion, metastasis and recurrence of HNSCC due to its substantial morbidity and mortality. The differential expression patterns of histone deacetylases (HDACs), a group of enzymes responsible for modifying histones and regulating gene expression, have been demonstrated in neoplastic tissues. However, there is limited knowledge regarding the role of HDACs in HNSCC. Consequently, this review aims to summarize the existing research findings and explore the potential association between HDACs and HNSCC, offering fresh perspectives on therapeutic approaches targeting HDACs that could potentially enhance the efficacy of HNSCC treatment. Additionally, the Cancer Genome Atlas (TCGA) dataset, CPTAC, HPA, OmicShare, GeneMANIA and STRING databases are utilized to provide supplementary evidence on the differential expression of HDACs, their prognostic significance and predicting functions in HNSCC patients.
Keywords: Epigenetic therapy; Head and neck squamous cell carcinoma; Histone deacetylases; Mechanism.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures




Similar articles
-
MLN4924 Suppresses head and neck squamous cell carcinoma progression by inactivating the mTOR signaling pathway via the NEDD8/CUL4/TSC2 axis.Int J Biochem Cell Biol. 2024 Dec;177:106696. doi: 10.1016/j.biocel.2024.106696. Epub 2024 Nov 18. Int J Biochem Cell Biol. 2024. PMID: 39566655
-
CCDC71L as a novel prognostic marker and immunotherapy target via lipid metabolism in head and neck squamous cell carcinoma.J Stomatol Oral Maxillofac Surg. 2024 Dec;125(6):101799. doi: 10.1016/j.jormas.2024.101799. Epub 2024 Feb 16. J Stomatol Oral Maxillofac Surg. 2024. PMID: 38367702
-
Far Posterior Approach for Rib Fracture Fixation: Surgical Technique and Tips.JBJS Essent Surg Tech. 2024 Dec 6;14(4):e23.00094. doi: 10.2106/JBJS.ST.23.00094. eCollection 2024 Oct-Dec. JBJS Essent Surg Tech. 2024. PMID: 39650795 Free PMC article.
-
The molecular characteristics of recurrent/metastatic HPV-positive head and neck squamous cell carcinoma: A systematic review of the literature.Clin Otolaryngol. 2024 Jul;49(4):384-403. doi: 10.1111/coa.14161. Epub 2024 Apr 24. Clin Otolaryngol. 2024. PMID: 38658385 Review.
-
Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.Clin Epigenetics. 2024 Apr 10;16(1):54. doi: 10.1186/s13148-024-01666-2. Clin Epigenetics. 2024. PMID: 38600608 Free PMC article. Review.
Cited by
-
5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity.Med Pharm Rep. 2024 Oct;97(4):488-506. doi: 10.15386/mpr-2777. Epub 2024 Oct 30. Med Pharm Rep. 2024. PMID: 39502764 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous